ACT NOW STUDY: ACTOS NOW FOR THE PREVENTION OF DIABETES

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这是一项8中心、研究者发起的随机临床试验，旨在测试吡格列酮与安慰剂对胰岛素抵抗和糖耐量受损成人糖尿病发生率、胰腺b细胞功能、颈动脉粥样硬化和动脉粥样硬化危险因素的影响。布坎南博士在研究设计中发挥了重要作用。南加州大学计划招收总共600个学科中的75个。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is an 8-center, investigator-initiated, randomized clinical trial to test the effects of pioglitazone vs. placebo on diabetes incident rates, pancreatic b-cell function, carotid atherosclerosis and risk factors for atherosclerosis in adults with insulin resistance and impaired glucose tolerance. Dr. Buchanan was instrumental in the study design. USC is planned to enroll and study 75 of the total 600 subjects.